Targeting novel immune check points in multiple myeloma and acute myeloid leukemia to improve allogeneic hematopoietic stem cell transplantation (A05)

• Subject Area: Immunology
• Term: from 2018 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 324392634

Within this CRC/TR subproject we will identify novel immune check point molecules (ICM) expressed by acute myeloid leukemia and multiple myeloma cells as well as by tumor-associated macrophages using a proprietary genome wide siRNA based screening approach. We will use established cell culture systems, preclinical mouse models and genome and proteome analyses of human samples to (i) functionally delineate the mode of action of selected ICM in modulating GvL after adoptive T cell therapy and in patients undergoing allo-HSCT and DLI and (ii) to explore the role of ICM expressed on target organs of GvHD in determining the risk and severity of GvHD after allo-HSCT

• DFG Programme: CRC/Transregios
• Subproject of: TRR 221: Modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation
• Applicant Institution: Universität Regensburg
• Project Head: Professor Dr. Philipp Beckhove